The document summarizes a genome-wide association study of genetic variants associated with LDL-cholesterol lowering in response to rosuvastatin therapy. The study identified four loci reaching genome-wide significance for either absolute or fractional LDL-C reduction, including variants near PCSK9, ABCG2, LPA, and APOE genes. Carrying more risk alleles at these loci was associated with greater LDL-C lowering in response to rosuvastatin. The study provides insights into genetic factors influencing inter-individual variability in statin treatment response.